Future studies with larger sample sizes should be also performed to further confirm the performance of the anti-TAA autoantibody panel we developed and whether it could be used as supplementary tool for the diagnosis of PCa in combination with prostate-specific antigen (PSA). The gene discussed is KLK3; the disease is posterior cortical atrophy.